Artículos del autor

solaci

Chronic Ischemic cardiopathy

TCT 2022 | FAME-3 Trial: post PCI FFR And IVUS in Patients with Three-Vessel Disease

We are well aware of the benefits of Fractional Flow Reserve (FFR) to assess coronary artery stenosis....
solaci -
Chronic Ischemic cardiopathy

TCT 2022 | BYPASS CTCA

Studies have shown that the use of computed tomography cardiac angiography (CTCA) prior invasive coronary angiography (ICA)...
solaci -
Structural heart disease

TCT 2022 | PROTECTED TAVR

Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of...
solaci -
Mitral valve

TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry

Approximately 1 in 5 patients admitted for cardiogenic shock (CS) were observed to have moderate to severe...
solaci -
Structural Heart Disease

TCT 2022 | CLASP II D TRIAL: Transcatheter Edge-to-Edge Repair for Mitral Regurgitation in Patients at Prohibitive Risk

The CLASP IID study was a prospective randomized study to assess the efficacy and effectiveness of the...
solaci -
Other

TCT 2022 | AMULET IDE: Events at 3 Years Using the AMULET Appendage Closure Device

The aim of this study was to assess the 3-year efficacy for the endpoints of the AMULET...
solaci -
Other

TCT 2022 | Pulmonary Artery Denervation in Primary Pulmonary Hypertension

Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced,...
solaci -
Peripheral Vascular Disease

SYMPLICITY HTN-3 Trial. Evolution at 3 Years

The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had...
solaci -